LBO — MOFFITT CANCER CENTER
IRR: 18.6% | MOIC: 2.35x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
18.6%
IRR
2.35x
MOIC
$1.6B
Entry EV
$2.6B
Exit EV
$810.0M
Equity Invested
Sources & Uses
S&UTotal · $1.6B| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $611.3M | 38.8% | |
| Sub Debt | $152.8M | 9.7% | |
| Equity | $810.0M | 51.5% | |
| Enterprise Value | $1.5B | 97.1% | |
| Transaction Fees | $45.8M | 2.9% | |
| Total Uses | $1.6B | 100.0% |
Interpretation
INTAt 2.35x MOIC and 18.6% IRR over 5 years, this deal meets the 15-20% range — acceptable with operational upside.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $244.0M |
| Exit Ev | $2.6B |
| Net Debt At Exit | $661.5M |
| Equity At Exit | $1.9B |
| Equity Invested | $810.0M |
| Total Value Created | $1.1B |
| Value From Growth | $957.7M |
| Value From Multiple | $76.4M |
| Value From Deleveraging | $102.6M |